Search Results

DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at BofA Securities 2024 Health Care Conference on Tuesday, May 14th, 2024 at 5:00 pm Pacific Daylight Time.

DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at Barclays Global Healthcare Conference 2024 on Wednesday, March 13, 2024, at 8:00 a.m. EDT.

DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at TD Cowen’s Health Care Conference 2024 on Monday, March 4, 2024, at 11:10 a.m. EST.

DaVita Inc, a leading provider of kidney care services, announced that it has agreed to terms on the expansion of its international operations in Brazil and Colombia, and its entry into Chile and Ecuador.

DaVita Inc. announced financial and operating results for the quarter ended September 30, 2023.

Today, The American Diabetes Association ® (ADA) and DaVita (NYSE: DVA), a leading provider of kidney care services, announced the expansion of a multi-year collaboration, focused on advancing chronic disease prevention, specifically addressing two of the most prevalent chronic conditions in the U.S. — diabetes and chronic kidney disease (CKD).

DaVita Inc., announced that it will hold its quarterly conference call to discuss second quarter results on Thursday, August 3rd, 2023, at 5:00 p.m. Eastern Time.

Dialysis giant DaVita on Thursday raised concerns over Novo Nordisk’s interim analysis of a kidney outcomes study of semaglutide, pointing to the potentially limited applicability of the findings.

DaVita Inc. announced that its Board of Directors appointed a new independent director, Wendy Schoppert, to join the Board, effective as of July 14, 2023.